AstraZeneca could skip asking the U.S. Food and Drug Administration for emergency-use authorization for its Covid-19 vaccine and instead pursue the more time-intensive application for full-fledged approval on.wsj.com
@WSJ4 years ago
U.S. health officials said AstraZeneca may have released outdated information from its Covid-19 vaccine trial, giving an incomplete view of efficacy data. The disclosure further clouds the drugmaker’s timeline for emergency use authorization in the U.S. on.wsj.com
@WSJ4 years ago
AstraZeneca said its Covid-19 vaccine was safe and 79% effective in U.S. trials and that it would prepare to request emergency-use authorization on.wsj.com
